Results

1–10 of 331 results for trial

Port Delivery System with Ranibizumab PDS for Continuous Treatment in DME and DR Additional Results from the Phase 3 Pagoda and Pavilion Trials
Dennis M. Marcus, MD
Annual Meeting Talks
2023
OTX-TKI for the Treatment of Neovascular Age-related Macular Degeneration 12-Month Results From a US Clinical Trial
Robert L. Avery, MD
Annual Meeting Talks
2023
Efficacy and Safety of Anti-High Temperature Requirement A1 aHtrA1 Fab in Geographic Atrophy GA Secondary to AMD GAllego Phase 2 Randomized Trial
David A. Eichenbaum, MD, FASRS
Annual Meeting Talks
2023
ZETA-1 Phase 2 Trial Safety and Tolerability Results for APX3330 a New Oral Ref-1 Inhibitor for the Treatment of Diabetic Retinopathy
Daniel Su, MD
Annual Meeting Talks
2023
ZETA-1 Phase 2 Trial Efficacy Results for APX3330 a Novel Oral Ref-1 Inhibitor for the Treatment of Diabetic Retinopathy
David R Lally, MD
Annual Meeting Talks
2023
MCO-010 Optogenetic Therapy for Severe Vision Loss in Stargardt Disease: 6-Month Outcomes From the Phase 2 STARLIGHT Trial
Allen C Ho, MD FASRS
Annual Meeting Talks
2023
Pooled Safety Analysis of Aflibercept 8 mg in the CANDELA PHOTON and PULSAR Trials
Philip J. Ferrone, MD, FASRS
Annual Meeting Talks
2023
Additional Visual and Anatomic Outcomes of Intravitreal Aflibercept Injection, 8 mg vs 2 mg: Post Hoc Analysis of the Phase 2 CANDELA Study
Priya Sharma Vakharia, MD
Annual Meeting Talks
2023
Exudative Age-Related Macular Degeneration Events from the OAKS and DERBY Clinical Trials of Pegcetacoplan in Geographic Atrophy
Roger A. Goldberg, MD, MBA
Annual Meeting Talks
2023
Time to Retinal Fluid Control With Faricimab vs Aflibercept in Patients With DME in the Phase 3 YOSEMITE/RHINE Trials
Aleksandra V. Rachitskaya, MD, FASRS
Annual Meeting Talks
2023